Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Non-Current Deferred Tax Liability data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, Non-Current Deferred Tax Liability fell 24.46% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, down 24.46%, while the annual FY2024 figure was $2.4 million, 24.46% down from the prior year.
  • Non-Current Deferred Tax Liability reached $2.4 million in Q3 2025 per RVMD's latest filing, roughly flat from $2.4 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $7.4 million in Q1 2021 and bottomed at $2.4 million in Q4 2024.
  • Average Non-Current Deferred Tax Liability over 5 years is $5.2 million, with a median of $7.0 million recorded in 2022.
  • Peak YoY movement for Non-Current Deferred Tax Liability: rose 5.07% in 2021, then plummeted 55.82% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $7.4 million in 2021, then dropped by 5.63% to $7.0 million in 2022, then crashed by 55.66% to $3.1 million in 2023, then dropped by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $2.4 million in Q3 2025, $2.4 million in Q2 2025, and $2.4 million in Q1 2025.